Tempus AI, Inc. (NASDAQ ... though demand checks remain positive. For AI DC, Blackwell continues to ramp well and even with GB200 delays, we expect Blackwell revenue to surpass Hopper during ...

CHICAGO, April 28, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop ...

Tempus AI, Inc. TEM is scheduled to report first-quarter fiscal 2025 results on May 6. In the last reported quarter, the company’s adjusted loss of 18 cents was wider than the Zacks Consensus ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology.

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock followed the announcement of a multiyear collaboration ...

Tempus AI announces a multi-year collaboration with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology. Tempus says the collaboration includes $200 million in data ...

Tempus AI is trading near yearly lows despite strong growth prospects, driven by the Ambry Genetics acquisition and robust organic growth. The company has innovative AI diagnostic services ...

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine with a market capitalization of $9.15 billion, announced the launch of Tempus Loop, a new platform designed to ...